相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Secreted PD-L1 variants mediate resistance to PD-L1 blockade therapy in non-small cell lung cancer
Bo Gong et al.
JOURNAL OF EXPERIMENTAL MEDICINE (2019)
PD-L1 promotes colorectal cancer stem cell expansion by activating HMGA1-dependent signaling pathways
Fang Wei et al.
CANCER LETTERS (2019)
A secreted PD-L1 splice variant that covalently dimerizes and mediates immunosuppression
Kathleen M. Mahoney et al.
CANCER IMMUNOLOGY IMMUNOTHERAPY (2019)
Identification and characterization of an alternative cancer-derived PD-L1 splice variant
Nadia B. Hassounah et al.
CANCER IMMUNOLOGY IMMUNOTHERAPY (2019)
Translational control of tumor immune escape via the eIF4F-STAT1-PD-L1 axis in melanoma
Michael Cerezo et al.
NATURE MEDICINE (2018)
Identification of CMTM6 and CMTM4 as PD-L1 protein regulators
Riccardo Mezzadra et al.
NATURE (2017)
Interferon Receptor Signaling Pathways Regulating PD-L1 and PD-L2 Expression
Angel Garcia-Diaz et al.
CELL REPORTS (2017)
Soluble PD-L1 as a Biomarker in Malignant Melanoma Treated with Checkpoint Blockade
Jun Zhou et al.
CANCER IMMUNOLOGY RESEARCH (2017)
The Potential Value of Immunotherapy in Colorectal Cancers: Review of the Evidence for Programmed Death-1 Inhibitor Therapy
James W. T. Toh et al.
CLINICAL COLORECTAL CANCER (2016)
Pembrolizumab versus Chemotherapy for PD-L1-Positive Non-Small-Cell Lung Cancer
Martin Reck et al.
NEW ENGLAND JOURNAL OF MEDICINE (2016)
Cdk5 disruption attenuates tumor PD-L1 expression and promotes antitumor immunity
R. Dixon Dorand et al.
SCIENCE (2016)
PD-L1 expression in human cancers and its association with clinical outcomes
Xin Wang et al.
ONCOTARGETS AND THERAPY (2016)
Prognostic significance of programmed death-1 and programmed death-ligand 1 expression in patients with esophageal squamous cell carcinoma
Kaiyan Chen et al.
ONCOTARGET (2016)
The emerging role of immunotherapy in colorectal cancer
David Lynch et al.
ANNALS OF TRANSLATIONAL MEDICINE (2016)
The Clothes Make the mRNA: Past and Present Trends in mRNP Fashion
Guramrit Singh et al.
ANNUAL REVIEW OF BIOCHEMISTRY, VOL 84 (2015)
Immune Checkpoint Targeting in Cancer Therapy: Toward Combination Strategies with Curative Potential
Padmanee Sharma et al.
CELL (2015)
Pembrolizumab (MK-3475) for patients (pts) with advanced colorectal carcinoma (CRC): Preliminary results from KEYNOTE-028
B. H. O'Neil et al.
EUROPEAN JOURNAL OF CANCER (2015)
PD-L1 expression as a potential predictive biomarker
Alberto Fusi et al.
LANCET ONCOLOGY (2015)
The impact of clinical characteristics on outcomes from maintenance therapy in non-small cell lung cancer: A systematic review with meta-analysis
Fei Zhou et al.
LUNG CANCER (2015)
PD-L1 Expression as a Predictive Biomarker in Cancer Immunotherapy
Sandip Pravin Patel et al.
MOLECULAR CANCER THERAPEUTICS (2015)
PD-1 Blockade in Tumors with Mismatch-Repair Deficiency
D. T. Le et al.
NEW ENGLAND JOURNAL OF MEDICINE (2015)
Nivolumab versus Everolimus in Advanced Renal-Cell Carcinoma
R. J. Motzer et al.
NEW ENGLAND JOURNAL OF MEDICINE (2015)
Emerging Roles of Disordered Sequences in RNA-Binding Proteins
Sara Calabretta et al.
TRENDS IN BIOCHEMICAL SCIENCES (2015)
PD-1 pathway inhibitors: The next generation of immunotherapy for advanced melanoma
Jason J. Luke et al.
ONCOTARGET (2015)
Expression of costimulatory molecules B7-H1, B7-H4 and Foxp3+ Tregs in gastric cancer and its clinical significance
Yiting Geng et al.
INTERNATIONAL JOURNAL OF CLINICAL ONCOLOGY (2015)
PD-1 blockade induces responses by inhibiting adaptive immune resistance
Paul C. Tumeh et al.
NATURE (2014)
PD-L1 Expression in Triple-Negative Breast Cancer
Elizabeth A. Mittendorf et al.
CANCER IMMUNOLOGY RESEARCH (2014)
Safety and Tumor Responses with Lambrolizumab (Anti-PD-1) in Melanoma
Omid Hamid et al.
NEW ENGLAND JOURNAL OF MEDICINE (2013)
The blockade of immune checkpoints in cancer immunotherapy
Drew M. Pardoll
NATURE REVIEWS CANCER (2012)
PD-L1 regulates the development, maintenance, and function of induced regulatory T cells
Loise M. Francisco et al.
JOURNAL OF EXPERIMENTAL MEDICINE (2009)
PD-1 and its ligands in tolerance and immunity
Mary E. Keir et al.
ANNUAL REVIEW OF IMMUNOLOGY (2008)
Collagen I-mediated up-regulation of N-cadherin requires cooperative signals from integrins and discoidin domain receptor 1
Yasushi Shintani et al.
JOURNAL OF CELL BIOLOGY (2008)
Programmed death-1 ligand 1 interacts specifically with the B7-1 costimulatory molecule to inhibit T cell responses
Manish J. Butte et al.
IMMUNITY (2007)
Loss of tumor suppressor PTEN function increases B7-H1 expression and immunoresistance in glioma
Andrew T. Parsa et al.
NATURE MEDICINE (2007)
Tumor B7-H1 is associated with poor prognosis in renal cell carcinoma patients with long-term follow-up
RH Thompson et al.
CANCER RESEARCH (2006)
Identification of a novel splice variant of human PD-L1 mRNA encoding an isoform-lacking Igv-like domain
XH He et al.
ACTA PHARMACOLOGICA SINICA (2005)
Cooperative B7-1/2 (CD80/CD86) and B7-DC costimulation of CD4+ T cells independent of the PD-1 receptor
T Shin et al.
JOURNAL OF EXPERIMENTAL MEDICINE (2003)
Engagement of the PD-1 immunoinhibitory receptor by a novel B7 family member leads to negative regulation of lymphocyte activation
GJ Freeman et al.
JOURNAL OF EXPERIMENTAL MEDICINE (2000)
分享论文
